Clinical Guideline for Wound Management in Pyoderma 
Gangrenosum

Shouyu Wang*; Lei Gao; Peng Shi; Tianqi Zhao; Xiaohong Sun

doi:10.70711/pmr.v3i2.8391

Clinical Guideline for Wound Management in Pyoderma Gangrenosum

Shouyu Wang*, Lei Gao, Peng Shi, Tianqi Zhao, Xiaohong Sun

Abstract

This guideline provides a practical framework for wound management in pyoderma gangrenosum (PG), an uncommon but destructive neutrophilic dermatosis. It defines target populations and exclusion criteria, outlines a "high suspicion-structured exclusion-risk stratification" diagnostic pathway, and emphasizes early systemic immunosuppression, minimally traumatic wound care, and strict control of pathergy.

Keywords

Pyoderma gangrenosum; Wound management; Clinical practice guideline

Full Text:

PDF

Included Database

References

[1] Ahronowitz I, Harp J, Shinkai K. Etiology and management of pyoderma gangrenosum: a comprehensive review. American Journal of

Clinical Dermatology. 2012;13(3):191-211.

[2] Alavi A, French LE, Davis MD, Brassard A, Kirsner RS. Pyoderma gangrenosum: An update on pathophysiology, diagnosis and treatment. American Journal of Clinical Dermatology. 2017;18(3):355-372.

[3] Bellini V, Lionetti G. Pimecrolimus cream 1% for the treatment of pyoderma gangrenosum. Journal of the European Academy of Dermatology and Venereology. 2008;22(1):113-114.

[4] Bhat RM. Pyoderma gangrenosum: An update. Indian Dermatology Online Journal. 2012;3(1):7-13.

[5] Brooklyn T, Dunnill G, Probert C. Diagnosis and treatment of pyoderma gangrenosum. BMJ. 2006;333(7560):181-184.

[6] Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo

controlled trial. Gut. 2006;55(4):505-509.

[7] Dissemond J. Treatment of pyoderma gangrenosum: Current options and future directions. Drugs. 2023;83(14):1273-1293.

[8] George C, Deroide F, Rustin M. Pyoderma gangrenosum a guide to diagnosis and management. Clinical Medicine. 2019;19(3):224-

228.

[9] Goldminz AM, Scheinman PL, Gottlieb AB. Ustekinumab for the treatment of pyoderma gangrenosum. Journal of the American Academy of Dermatology. 2012;67(5):e217-e219.

[10] Heffernan MP, Anadkat MJ, Smith DI. Adalimumab for pyoderma gangrenosum. Archives of Dermatology. 2007;143(7):881-885.

[11] Hobbs MM, Ortega-Loayza AG. Pyoderma gangrenosum: from historical perspectives to emerging investigations. International Wound

Journal. 2020;17(5):1255-1265.

[12] Low LM, Tan CS, Cheng JWM, Chong WS. Ustekinumab in the treatment of recalcitrant pyoderma gangrenosum: a case series. Australasian Journal of Dermatology. 2018;59(4):e273-e277.

[13] ?yko M, Szelepaj?o A, ?aczma?ska I, Jankowska-Konsur A. The Pathophysiology and Treatment of Pyoderma Gangrenosum. International Journal of Molecular Sciences. 2024;25(4):2440-2440.

[14] Maverakis E, Marzano AV, Le ST, et al. Diagnostic criteria of ulcerative pyoderma gangrenosum: a Delphi consensus of international

experts. JAMA Dermatology. 2018;154(4):461-466.

[15] Partridge ACR, Bai JW, Rosen CF, Walsh SR. Systemic monotherapy for pyoderma gangrenosum: a systematic review. British Journal

of Dermatology. 2018;179(2):290-295.

DOI: http://dx.doi.org/10.70711/pmr.v3i2.8391

Refbacks

There are currently no refbacks.